Avadel Pharmaceuticals will host a conference call on March 3, 2025, to discuss Q4 and full-year financial results.
Quiver AI Summary
Avadel Pharmaceuticals plc announced that it will hold a conference call and live webcast on March 3, 2025, at 8:30 a.m. ET to provide a corporate update and discuss its financial results for the fourth quarter and full year ending December 31, 2024. The event will be accessible through the investor relations section of the company's website, with a replay available for 90 days afterward. Avadel is known for its innovative approach in biopharmaceuticals, highlighted by its commercial product LUMRYZ™, the first FDA-approved once-at-bedtime oxybate for treating narcolepsy in patients aged 7 and older. For further information, interested participants can register for the call and access additional details on Avadel’s website.
Potential Positives
- The announcement of a conference call and live webcast highlights the company's commitment to transparency and shareholder communication regarding its financial results and corporate updates.
- The timing of the call, shortly after the conclusion of the fourth quarter and full year of 2024, indicates proactive engagement with investors and timely dissemination of important information.
- The reference to the FDA approval of Avadel’s commercial product, LUMRYZ™, underscores the company’s innovative contributions to the biopharmaceutical industry and its focus on addressing specific patient needs.
- The accessibility of the conference call via web and its archival availability for 90 days demonstrates an emphasis on inclusive and accessible investor relations practices.
Potential Negatives
- The reliance on a scheduled conference call and webcast for financial results may indicate a lack of proactive communication strategy, especially if significant issues are anticipated in the outcomes.
- The announcement does not provide any preliminary financial results or expectations, which might raise concerns among investors about the company's current performance and outlook.
- Discussing financial results in a future webcast, without prior disclosures, may suggest that the company's recent performance is not robust enough to share ahead of time, potentially leading to negative speculation.
FAQ
When is the Avadel Pharmaceuticals conference call scheduled?
The conference call is scheduled for 8:30 a.m. ET on Monday, March 3, 2025.
How can I access the live webcast of the conference call?
The live audio webcast can be accessed via the investor relations section of Avadel's website, www.avadel.com.
Will the conference call be available for replay?
Yes, a replay of the webcast will be archived on Avadel’s website for 90 days after the event.
Who can I contact for investor inquiries about Avadel?
Please contact Austin Murtagh at Precision AQA via email at [email protected].
What is LUMRYZ™ and its significance?
LUMRYZ™ is Avadel's approved medication for treating cataplexy and excessive daytime sleepiness in narcolepsy patients aged 7 and older.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AVDL Insider Trading Activity
$AVDL insiders have traded $AVDL stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AVDL stock by insiders over the last 6 months:
- ERIC J ENDE purchased 30,000 shares for an estimated $235,218
- GEOFFREY MICHAEL GLASS has made 2 purchases buying 20,279 shares for an estimated $199,640 and 0 sales.
- GREGORY J DIVIS (Chief Executive Officer) has made 2 purchases buying 10,000 shares for an estimated $99,706 and 0 sales.
- PETER J. THORNTON purchased 10,000 shares for an estimated $80,450
- THOMAS S MCHUGH (Chief Financial Officer) has made 2 purchases buying 7,300 shares for an estimated $76,451 and 0 sales.
- LINDA PALCZUK has made 2 purchases buying 8,000 shares for an estimated $70,207 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AVDL Hedge Fund Activity
We have seen 87 institutional investors add shares of $AVDL stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SEAS CAPITAL LP added 2,042,669 shares (+90.6%) to their portfolio in Q4 2024, for an estimated $21,468,451
- WOODLINE PARTNERS LP removed 1,185,492 shares (-70.3%) from their portfolio in Q4 2024, for an estimated $12,459,520
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 994,738 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $13,045,988
- UBS GROUP AG added 963,556 shares (+158.7%) to their portfolio in Q4 2024, for an estimated $10,126,973
- BRANDES INVESTMENT PARTNERS, LP added 798,415 shares (+58.1%) to their portfolio in Q4 2024, for an estimated $8,391,341
- JANUS HENDERSON GROUP PLC added 753,332 shares (+5.7%) to their portfolio in Q4 2024, for an estimated $7,917,519
- BRAIDWELL LP added 716,787 shares (+21.2%) to their portfolio in Q4 2024, for an estimated $7,533,431
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024.
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com . A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
[email protected]
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
[email protected]
(609) 273-3162
